Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 8/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 8/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955430 | 0.88 | KDR (0.45) | CSNK1DCSNK1EKDRMETAURKA | |
| SCHEMBL252104 | 0.85 | CSNK1D (0.35) | CSNK1DCSNK1EKDR | |
| SCHEMBL5954781 | 0.82 | GSK3B (0.46) | CSNK1DCSNK1E | |
| SCHEMBL23761188 | 0.79 | KDR (0.54) | CSNK1DCSNK1EKDRMETAURKA | |
| SCHEMBL5954647 | 0.78 | KDR (0.43) | CSNK1DCSNK1EKDRMET | |
| SCHEMBL253801 | 0.77 | CSNK1D (0.51) | CSNK1DCSNK1EKDRJAK1MET | |
| SCHEMBL5955497 | 0.77 | KDR (0.42) | CSNK1DCSNK1EKDRMET | |
| SCHEMBL251711 | 0.77 | CSNK1D (0.53) | CSNK1DCSNK1EKDRJAK1MET | |
| SCHEMBL1551292 | 0.76 | CSNK1D (0.52) | CSNK1DCSNK1EKDRMETAURKA | |
| SCHEMBL5954875 | 0.76 | CSNK1D (0.52) | CSNK1DCSNK1EKDRJAK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | CSNK1D 225/4885CSNK1E 119/4885KDR 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.